Skip to main content
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 2025 Mar 12;151(3):108. doi: 10.1007/s00432-025-06103-2

Correction: Recombinant human endostatin improves anti-tumor efficacy of paclitaxel by normalizing tumor vasculature in Lewis lung carcinoma

Guichun Huang 1, Longbang Chen 1,
PMCID: PMC11903533  PMID: 40072676

Correction to: Journal of Cancer Research and Clinical Oncology (2010) 136:1201–1211 10.1007/s00432-010-0770-6

In Fig. 2 of this article, incorrect data was originally displayed in panels A-F. The published incorrect version and the corrected version of figure 2 are given below.

Published incorrect version: graphic file with name 432_2025_6103_Figa_HTML.jpg

Corrected version:

Fig. 2.

Fig. 2

Microvascular density of Lewis lung carcinoma decreased by rh-endostatin. When the implanted tumor reached a volume of about 100 mm3, rh-endostatin was given 5 mg/kg subcutaneously for consecutive 7 days with normal saline as control. On days 3, 6, and 9, mice (n = 5) were killed and tumor samples were stained by anti-CD31 antibody. ac Typical photographs represented the microvessels in Lewis lung carcinoma in control group on days 3, 6, and 9, respectively. df Typical photographs represented the microvessels in Lewis lung carcinoma in rh-endostatin group on days 3, 6, 9, respectively. Scale bar 25 μm. g Histogram of mean microvascular density at different time points. Microvascular density was reduced by rh-endostatin and the difference was significant on day 9 (p = 0.013), bars SEM. *p < 0.05

The original article has been corrected.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES